Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;10(6):1655-1668.
doi: 10.1007/s40744-023-00602-9. Epub 2023 Oct 15.

Psoriasis and Psoriatic Arthritis Have a Major Impact on Quality of Life and Depressive Symptoms: A Cross-Sectional Study of 300 Patients

Natalie Frede  1 , Sonja Hiestand  2 , Franziska Schauer  3 , Dominique Endres  4 , Ludger Tebartz van Elst  4 , Markus Zeisbrich  2 , Nils Craig-Mueller  2 , Stephanie Finzel  2 , Jens Thiel  2   5 , Reinhard E Voll  2 , Christoph Schempp  3 , Nils Venhoff  2
Affiliations

Psoriasis and Psoriatic Arthritis Have a Major Impact on Quality of Life and Depressive Symptoms: A Cross-Sectional Study of 300 Patients

Natalie Frede et al. Rheumatol Ther. 2023 Dec.

Abstract

Introduction: Psoriasis (Pso) and psoriatic arthritis (PsA) can reduce the quality of life (QoL) and are known to be associated with depression. Within this study, we aimed to assess the burden of disease, functional capacity, quality of life, and depressive symptoms and identify factors predicting functional impairment and depression in patients with psoriatic disease.

Methods: A cross-sectional survey was conducted in a cohort of 300 patients with psoriatic disease including 150 patients from a university hospital dermatology outpatient clinic and 150 patients from a university hospital rheumatology outpatient clinic. Questionnaire-based assessment of signs of arthritis (Psoriasis Epidemiology Screening Tool; PEST), functional status (Functional Questionnaire Hannover; FFbH), quality of life (World Health Organization Quality of Life Brief Version; WHOQOL-BREF), and depressive symptoms (Patient health questionnaire 9; PHQ-9) and retrospective medical chart analysis were performed.

Results: Despite treatment, burden of disease was high. Joint pain was reported in multiple regions in patients with Pso (n = 111) and patients with PsA (n = 189), but with differences in frequency and distribution patterns of symptoms. Functional impairment in everyday life was independently associated with diagnosis of PsA (odds ratio [OR] 9.56, p = 0.005), depressive symptoms (OR 5.44, p < 0.001) and age (OR 1.04, p = 0.033). At least mild depressive symptoms were demonstrated in 54% and 69% of patients with Pso and PsA, respectively. In a logistic regression model, depressive symptoms were independently associated with functional impairment (OR 4.50, p = 0.003), axial complaints (OR 2.80, p = 0.030), diagnosis of psoriatic arthritis (OR 2.69, p = 0.046), and number of joint regions with complaints (OR 1.10, p = 0.032).

Conclusion: Functional impairment, QoL, and depressive symptoms are mutually interdependent. Early diagnosis of PsA and initiation of anti-inflammatory therapy are essential to avoid long-term damage, disability, and mental health complications. However, despite therapy many patients with PsA, and especially female patients, report a substantial residual disease burden due to their psoriatic disease which will need to be addressed by a more patient-centered approach.

Keywords: Depression; Functional impairment; Psoriasis; Psoriatic arthritis (PsA); Quality of life.

PubMed Disclaimer

Conflict of interest statement

Nils Venhoff: Speaker honoraria: AbbVie, Novartis, UCB, Bristol-Myers Squibb, Pfizer; Advisory Boards: AbbVie, Novartis, UCB; Research grants: Bristol-Myers Squibb, Novartis, Pfizer. Jens Thiel: Speaker honoraria: GSK, BMS, AstraZeneca, Abbvie, UCB, Lilly; Advisory Boards: Novartis, GSK, AstraZeneca, Lilly. Grant/research support from: BMS, Novartis. Reinhard E. Voll: Speaker fees: AbbVie, Amgen, BMS, Boehringer-Ingelheim, GSK, Janssen-Cilag, Hexal, Novartis, Pfizer, Roche; Advisory boards: AbbVie, Amgen, Boehringer-Ingelheim, BMS, GSK, Janssen-Cilag, Hexal, Neutrolis, Novartis, Sanofi, Takeda; Unrestricted research grants: Amgen, BMS, Novartis, Pfizer. Natalie Frede received travel grants from AbbVie, Janssen, Sobi, Pfizer. Sonja Hiestand, Franziska Schauer, Dominique Endres, Ludger Tebartz van Elst, Markus Zeisbrich, Nils Craig-Mueller, Stephanie Finzel and Christoph Schempp have nothing to declare.

Figures

Fig. 1
Fig. 1
Joint distribution and affected disease domains. a Self-reported regions with joint pain or joint problems in psoriasis (n = 111) and psoriatic arthritis (n = 189). The most commonly affected regions were hands/fingers, knees, feet/toes, and lower back in patients with PsA; hands/fingers, feet/toes, lower back, and ankles in patients with Pso with a PEST score ≥ 3 (n = 31); knees, hands/fingers, and shoulders in patients with Pso with a PEST score < 3 (n = 80). b Number of affected disease domains (self-reported) out of six possible domains (skin psoriasis, nail involvement, peripheral arthritis, axial disease, enthesitis, dactylitis). PEST Psoriasis Epidemiology Screening Tool, PsA psoriatic arthritis, Pso psoriasis
Fig. 2
Fig. 2
Depressive symptoms and quality of life. a Depressive symptoms determined by PHQ-9. Patients with PsA shown in dark blue, patients with Pso with PEST ≥ 3 in light blue, patients with Pso with PEST < 3 in white. b Pearson’s correlations between clinical data, quality of life, and depressive symptoms. Numbers within the graph represent Pearson’s R values. Red color indicates positive correlation, blue negative correlation. BMI body mass index, QoL quality of life, FFbH Functional Questionnaire Hannover, PEST Psoriasis Epidemiology Screening Tool, PHQ-9 Patient health questionnaire 9 (depressive symptoms), PsA psoriatic arthritis, Pso psoriasis, WHOQOL D1 World Health Organization Quality of Life Domain 1 (= physical health-related QoL), D2 = mental HRQoL, D3 = social QoL, D4 = environmental QoL
See this image and copyright information in PMC

References

    1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. - PubMed
    1. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–65.e19. - PubMed
    1. Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242–248. - PubMed
    1. Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72(5):736–740. - PubMed
    1. Eder L, Chandran V, Gladman DD. What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis? Curr Opin Rheumatol. 2015;27(1):91–98. - PubMed